… investigation of ocrelizumab in patients with primary progressive multiple sclerosis. Here,
we report results from a phase 3, randomized, parallel-group, double-blind, placebo-controlled …

… in phase 2 and 3 studies, leading to the approval of OCR for the treatment of patients with
relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). …

… switching from placebo, earlier and continuous ocrelizumab treatment … ocrelizumab in
primary progressive disease, progression remains an important unmet need in multiple sclerosis. …

… Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive
multiple sclerosis from the phase III ORATORIO study. Int J MS Care 2018; 20(Suppl 1): 1–…

… The first event occurred in an IFN β-1a-treated patient in association with the initial
infusion of ocrelizumab placebo and consisted of severe (CTCAE grade 3) balance disorder, …

… ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple
sclerosis (… Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered. …

… Key exclusion criteria were secondary or primary progressive multiple sclerosis; disease
duration more than 15 years in patients with an EDSS of 2 or less; known history or presence of …

… disease activity in primary progressive multiple sclerosis (PPMS). In the placebo-controlled
phase III ORATORIO study (NCT01194570), we investigated the effect of ocrelizumab on this …

… However, in about 10% of the cases, the disease starts with a progressive disability worsening
without remission periods. This form of the disease is known as primary progressive MS (…

… Ocrelizumab (Ocrevus ® ) is a humanized anti-CD20 monoclonal antibody approved for
the treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …